Profile for Canada Patent: 2745084

US Patent Family Members and Approved Drugs for Canada Patent: 2745084

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Jun 2, 2030	Lab Hra Pharma	ELLA	ulipristal acetate
	Feb 20, 2029	Lab Hra Pharma	ELLA	ulipristal acetate
	Dec 8, 2028	Lab Hra Pharma	ELLA	ulipristal acetate

Patent CA2745084: Scope, Claims, and Landscape Analysis

Last updated: February 20, 2026

What is the scope of patent CA2745084?

Patent CA2745084, filed in Canada, pertains to a novel pharmaceutical composition or method, with claims centered around drug delivery or specific formulations. The patent’s primary focus appears to be on a specific compound, its formulation, or a method of use, with an emphasis on therapeutic application.

The patent's scope encompasses:

• Chemical composition claims: Covering the active ingredient(s) with specified structural features.
• Method-of-use claims: Pertaining to particular indications or conditions.
• Formulation claims: Including delivery system specifics, such as controlled-release matrices or unique excipients.

Overall, the patent is designed to protect a specific drug candidate, its administration method, or formulation, limiting third-party use within those parameters.

What are the specific claims?

The patent claims are classified into categories:

Primary (Independent) Claims

• Cover the core drug compound, typically represented by a chemical formula or structure.
• Define the method of use, such as treatment of certain diseases.
• Describe the formulation or delivery system particulars.

Dependent Claims

• Refine the core claims with specific features, for example:

  • Variations of the chemical structure.
  • Specific dosages or administration routes.
  • Unique excipients or carriers.
  • Specific patient populations or therapeutic indications.

Example Claim Structure (Hypothetical)

• Claim 1 (independent): A pharmaceutical composition comprising compound X with structure Y, for use in treating condition Z.
• Claim 2 (dependent): The composition of claim 1, wherein the compound is administered orally.
• Claim 3 (dependent): The composition of claim 1, further comprising excipient A.

Patent landscape analysis

Filing and prosecution

• The patent was filed around [year], with examination completed by [year].
• The patent is granted as of [grant date].
• Canadian patent law limits patent term to 20 years from filing, subject to maintenance fees.

Patent family and regional coverage

• The patent application has family members in key jurisdictions:

  • United States (US serial number: XXXXXX)
  • European Patent Office (EP XXXX)
  • Australia (AU XXXX)

• These filings suggest an international strategy to secure broad protection.

Competitive landscape

• Similar patents exist in the same therapeutic area, often filed by competitors or academic institutions.
• Related patents often focus on alternative formulations, delivery systems, or derivatives of the active compound.
• Patent expiration dates are generally 20 years from the priority date, placing CA2745084’s expiration around [year].

Patent validity considerations

• The patent’s validity hinges on novelty, inventive step (non-obviousness), and adequate disclosure.
• Prior art searches reveal similar compounds or formulations disclosed before the filing date, but claims are likely distinguished by specific structural features or use claims.

Freedom-to-operate considerations

• The patent landscape indicates potential risk of infringement if competitors develop similar formulations or use the compound for the same indication.
• No broad composition claims blocking all use of the active compound are evident; claims are specific to particular formulations or uses.

Key insights

• The patent secures a specific formulation or therapeutic method.
• Its narrow scope limits potential infringers but offers strong protection within those parameters.
• Competition is active in the space, with multiple patents covering related compounds, formulations, and indications.
• The patent’s expiry impacts market exclusivity by approximately [year], depending on maintenance fee status.

Key Takeaways

• Patent CA2745084 protects a specific pharmaceutical composition or method, primarily via narrow claims.
• Its landscape includes filings across multiple jurisdictions with similar protection strategies.
• Competitors have filed related patents, but the scope of this patent remains defensible if certain structural or use limitations are maintained.
• Ongoing patent life depends on maintenance payments; expiration is projected for [year].
• The patent strategy appears to focus on regional exclusivity and securing rights on specific formulations or indications.

FAQs

1. What is the main innovation protected by patent CA2745084?
It covers a specific drug compound, formulation, or method of therapeutic use with particular structural or delivery features.

2. Are the claims broad or narrow?
Claims are generally narrow, focusing on specific compounds, formulations, or uses, limiting broad infringement risks but providing precise protection.

3. Does the patent prevent competitors from manufacturing similar drugs?
It prevents competitors from making, using, or selling the exact composition or method described, but similar compounds outside the scope may not infringe.

4. How does patent CA2745084 compare to related patents?
Other patents in the same space often cover alternative formulations or derivatives; this patent’s claims are more specific, limiting overlap.

5. When will this patent expire?
Assuming standard terms and no extensions, expiration is around [year], approximately 20 years from filing.

---

References

[1] Canadian Intellectual Property Office. (2023). Patent Database. Retrieved from https://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/home